Work

Abstract LB-231: Phase Ib dose escalation and biomarker study of MK2206 in combination with standard doses of weekly paclitaxel in patients with locally advanced or metastatic solid tumors with expansion in advanced breast cancer

Year: 2012

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2012-lb-231

Authors: Ana M. Gonzalez-Angulo, Ian Krop, Sarina Piha-Paul, Yisheng Li, Kirk S. Culotta, Stacy Moulder-Thompson, Apostolia Tsimberidou, Vivianne M. Velez-Bravo, Timothy L. Madden, Lisa M. Norberg, Austin Doyle, Eric P. Winder, Gordon B. Mills, Funda Meric-Bernstam, Razelle Kurzrock

Institutions: The University of Texas MD Anderson Cancer Center, Dana-Farber Cancer Institute, National Institutes of Health

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2076487518

Cites:

Cited by: 1

Related to: 10